Page last updated: 2024-08-23

etoposide and ixazomib

etoposide has been researched along with ixazomib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W	1

Trials

1 trial(s) available for etoposide and ixazomib

Article	Year
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Patient Safety; Remission Induction; Salvage Therapy; Treatment Outcome	2019

Article

Year

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Patient Safety; Remission Induction; Salvage Therapy; Treatment Outcome

2019